Omnaris martinez biography of martin

  • Inhaled corticosteroids (ICS) are one of the most frequently prescribed treatments in the management of respiratory inflammatory diseases.
  • In these studies, the LABA/ICS combination resulted in a lower rate of exacerbations and improved quality of life, symptoms, and lung function.
  • Descriptive statistics were summarized for demographic factors and clinical characteristics, including medical history, healthcare resource utilisation, blood.

    • •

    Full Text

    Inhaled corticosteroids (ICS) are one of the most frequently prescribed treatments in the management of respiratory inflammatory diseases. Indeed, ICS are extensively used in both asthma1 and COPD (particularly those manifesting peripheral eosinophilia),2,3 and both of these conditions are highly prevalent in the general population.4,5 In the vast array of commercially available ICS, there is a high degree of variability among the various formulations, including different chemical and molecular compositions, inhalation devices, formulations of the compound (dry-powder, solution, metered-doses), particle sizes, and being either in isolation or combined with other pharmacological agents such as short-acting or long-acting bronchodilators.6

    It has been estimated that around a billion people suffer from obstructive sleep apnea (OSA) globally.7 In this context, complex associations have been identified between OSA and other respiratory conditions that are usually treated wi

    •

    Inhaled corticosteroids in children with persistent asthma: dose‐response effects on growth

    Abstract

    Background

    Inhaled corticosteroids (ICS) are the first‐line treatment for children with persistent asthma. Their potential for growth suppression remains a matter of concern for parents and physicians.

    Objectives

    To assess whether increasing the dos of ICS is associated with slower linear growth, weight gain and skeletal maturation in children with asthma.

    Search methods

    We searched the Cochrane Airways Group Specialised förteckning of trials (CAGR) and the ClinicalTrials.gov website up to March 2014.

    Selection criteria

    Studies were eligible if they were parallel‐group randomised trials evaluating the impact of different doses of the same ICS using the same device in both groups for a minimum of three months in children one to 17 years of age with persistent asthma.

    Data collection and analysis

    Two review authors ascertained methodological quality independently using the Coc

    •

    . Author manuscript; available in PMC: 2016 Oct 25.

    Published in sista edited form as: Pulm Pharmacol Ther. 2015 May 5;32:130–136. doi: 10.1016/j.pupt.2015.04.001

    Abstract

    Corticosteroids are frequently prescribed anti-inflammatory medications. Inhaled corticosteroids (ICS) are indicated for Chronic Obstructive Pulmonary Disease (COPD) and asthma. ICSs are associated with a decrease in exacerbations and improved quality of life in COPD, however multiple studies have linked the chronic use of ICSs with an increased risk of developing pneumonia, though the effect on mortality is unclear. We review the association of ICS with the risk of pneumonia and the implications on clinical outcomes.

    Keywords: pneumonia, inhaled corticosteroids, chronic obstructive pulmonary disease

    1. Introduction

    Pneumonia is the leading cause of death related to infectious disease in developed countries and the eighth leading cause of death overall in the United States (US). In the US, pneumonia occu

  • omnaris martinez biography of martin